Welcome to our dedicated page for Axsome Therapeut news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeut stock.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on central nervous system (CNS) conditions, and its news flow reflects both commercial performance and clinical development across this neuroscience portfolio. On this page, readers can follow AXSM news related to its FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as updates on its late-stage and other development programs.
Company announcements frequently cover net product revenue for AUVELITY, SUNOSI, and SYMBRAVO, as reported in quarterly financial results and preliminary revenue updates. These releases, often furnished to the SEC via Form 8-K, provide insight into prescription trends, payer coverage metrics, and the contribution of each product to Axsome’s overall revenue base.
Axsome’s news also highlights key clinical and regulatory milestones. Examples include initiation of the FORWARD Phase 3 trial of AXS-14 in fibromyalgia, FDA acceptance and Priority Review of a supplemental New Drug Application for AXS-05 in Alzheimer’s disease agitation, and pre-NDA meeting outcomes supporting an NDA submission for AXS-12 in narcolepsy. Additional items describe progress of solriamfetol in multiple Phase 3 programs and the acquisition of AZD7325 for potential use in epilepsy.
Investors and followers of AXSM stock can use this news feed to monitor earnings releases, pipeline data presentations at scientific meetings, regulatory designations, business development transactions, and Axsome’s participation in healthcare and biopharma investor conferences. Bookmarking this page allows for efficient tracking of how Axsome advances its CNS portfolio and communicates with the market over time.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in June 2025:
- William Blair 45th Annual Growth Stock Conference - June 3, 2025, at 10:40 a.m. CT in Chicago
- Jefferies Global Healthcare Conference - June 5, 2025, at 2:35 p.m. ET in New York
- Goldman Sachs 46th Annual Global Healthcare Conference - June 9, 2025, at 2:40 p.m. ET in Miami Beach
Live webcasts will be available on Axsome's website, with replays accessible for approximately 30 days after each event.
Axsome Therapeutics (NASDAQ: AXSM) has reached a settlement agreement with Hetero Labs Ltd. regarding patent litigation for its drug SUNOSI® (solriamfetol). The litigation arose from Hetero's submission of an Abbreviated New Drug Application seeking approval for a generic version of SUNOSI. Under the settlement terms, Axsome will grant Hetero a license to sell its generic version starting either September 1, 2040 (if pediatric exclusivity is granted) or March 1, 2040 (without pediatric exclusivity), subject to FDA approval. The agreement will be reviewed by the U.S. Federal Trade Commission and Department of Justice. Similar patent litigation with other parties remains pending.
Axsome Therapeutics (NASDAQ: AXSM) has secured a $570 million term loan and revolving credit facility with Blackstone, replacing its previous Hercules Capital term loan. The facility consists of a $500 million term loan and a $70 million revolving credit facility. The company initially drew $120 million to retire its previous loan.
The new facility offers improved terms, including interest rates of SOFR plus 4.75% for the term loan and SOFR plus 4.0% for the revolving credit facility, with a 60-month interest-only period and maturity in May 2030. Additionally, Blackstone purchased $15 million of Axsome common stock at $107.14 per share. The company can access an additional $250 million at its option, with another $200 million available subject to Blackstone's approval.
Axsome Therapeutics (NASDAQ: AXSM) is partnering with Mental Health America (MHA) to promote Mental Health Month in May 2025. As part of MHA's "Light Up Green" initiative, Axsome's NYC headquarters at One World Trade Center will be illuminated in green to raise mental health awareness.
The collaboration highlights concerning mental health statistics in the US: nearly 1 in 4 adults live with mental illness, and more than 1 in 8 people aged 12 or older reported feeling depressed in the past two weeks. Almost 90% of people with depression experience difficulties with work, home, or social activities.
The initiative provides various resources including MHA's Mental Health Month Action Guide, ADAA's Mental Health Webinars, and NAMI's awareness campaign. The 988 Suicide & Crisis Lifeline is available 24/7 for those in crisis.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on CNS disorders, has announced its participation in four major investor conferences in May 2025:
- Citizens Life Sciences Conference - May 7, 1:30 PM ET in New York
- BofA Securities Health Care Conference - May 13, 3:00 PM PT in Las Vegas
- RBC Capital Markets Global Healthcare Conference - May 20, 3:05 PM ET in New York
- Mizuho Neuro & Ophthalmology Summit - May 21 in New York
Live webcasts will be available for the Citizens, BofA, and RBC conferences through the company's website at axsome.com, with replays accessible for approximately 30 days after each event.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, before U.S. markets open.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring management discussion of results and business updates. Investors can join via phone at (877) 405-1239 (domestic) or +1 (201) 389-0851 (international), or watch the webcast through Axsome's website. A replay will be available online for approximately 30 days after the event.
Axsome Therapeutics (NASDAQ: AXSM) announced multiple presentations at the 2025 American Academy of Neurology Annual Meeting in San Diego. The presentations showcase results from two pivotal Phase 3 trials: the ACCORD-2 trial of AXS-05 for Alzheimer's disease agitation and the SYMPHONY trial of AXS-12 for narcolepsy.
The ACCORD-2 results were accepted as a late-breaking abstract, highlighting the efficacy and safety of AXS-05 in a randomized withdrawal double-blind placebo-controlled study. Additionally, the company will present data from a network meta-analysis comparing SYMBRAVO® (AXS-07) to oral CGRPs for acute migraine treatment.
Key presentations include Dr. Michael J. Thorpy's discussion of the SYMPHONY trial results and the CRESCENDO survey findings on narcolepsy Type 1 patients' symptom burden and quality of life. Dr. Stephanie Nahas will present the comparative efficacy analysis of AXS-07 versus gepants for migraine treatment.